Literature DB >> 28129962

Impact of Electrical Cardioversion on Quality of Life for the Treatment of Atrial Fibrillation.

Roopinder K Sandhu1, Marcie Smigorowsky2, Evan Lockwood3, Anamaria Savu4, Padma Kaul5, Finlay A McAlister6.   

Abstract

BACKGROUND: Despite being a common intervention to restore sinus rhythm in patients with atrial fibrillation (AF), limited data exist on the impact of electrical cardioversion on quality of life (QoL) outcomes in clinical practice.
METHODS: This was a prospective cohort study of consecutive patients with AF referred for outpatient electrical cardioversion at 2 hospitals in Edmonton from 2013-2014. Baseline demographics, clinical characteristics, medications, and procedure details were obtained. QoL was assessed at baseline and at 3 months using the global Short-Form Health Survey (SF-36) and the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire.
RESULTS: One hundred patients underwent electrical cardioversion and completed follow-up. The median age was 62 years (interquartile range, 56-68 years) and 80% were men; the majority had nonparoxysmal AF (90%) with a mean left ventricular ejection fraction of 50.0% (± 12.4). At baseline, scores were lower than those reported from healthy individuals across all domains of the SF-36. The overall mean AFEQT score was 55.6 ± 24.4, and the domain-specific scores were as follows: symptoms, 66.2 ± 26.6; daily activities, 48.5 ± 29.5; treatment concerns, 57.6 ± 25.8; and treatment satisfaction, 56.7 ± 26.1. There were significant improvements in the vast majority of the SF-36 and AFEQT domains for the 51 patients who maintained sinus rhythm at 3 months. Patients who were in AF by 3 months demonstrated improvements in the AFEQT treatment concern score (P = 0.02) and SF-36 emotional role value (P < 0.01) compared with baseline values, which may be the result of treatment expectations related to cardioversion.
CONCLUSIONS: There are significant QoL benefits for patients who maintain sinus rhythm after electrical cardioversion.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 28129962     DOI: 10.1016/j.cjca.2016.11.013

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  4 in total

Review 1.  Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis.

Authors:  Natale Daniele Brunetti; Nicola Tarantino; Luisa De Gennaro; Michele Correale; Francesco Santoro; Matteo Di Biase
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

2.  Sex Differences in Quality of Life in Patients With Atrial Fibrillation: A Systematic Review.

Authors:  Linn Arvidsson Strømnes; Helene Ree; Knut Gjesdal; Inger Ariansen
Journal:  J Am Heart Assoc       Date:  2019-04-16       Impact factor: 5.501

3.  Stroke due to Left Atrial Appendage Thrombus after Pulmonary Vein Isolation despite Novel Oral Anticoagulant: A Case Report.

Authors:  Woon Hyung Chae; Heinrich Wieneke; Iryna Dykun; Cornelius Deuschl; Martin Köhrmann; Benedikt Frank
Journal:  Case Rep Neurol       Date:  2021-04-12

4.  Health literacy, health-related quality of life, and atrial fbrillation.

Authors:  Kara E Montbleau; Deandre King; Lori Henault; Jared W Magnani
Journal:  Cogent Med       Date:  2017-12-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.